tradingkey.logo
tradingkey.logo
Search

TriSalus Life Sciences Inc

TLSI
Add to Watchlist
4.690USD
+0.230+5.16%
Close 07/02, 13:00ETQuotes delayed by 15 min
288.03MMarket Cap
LossP/E TTM

TradingKey Stock Score of TriSalus Life Sciences Inc

Currency: USD Updated: 2026-07-02

Key Insights

TriSalus Life Sciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 107 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TriSalus Life Sciences Inc's Score

Industry at a Glance

Industry Ranking
107 / 387
Overall Ranking
229 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

TriSalus Life Sciences Inc Highlights

StrengthsRisks
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.91% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 45.15M.
Fairly Valued
The company’s latest PE is -3.30, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 14.73M shares, increasing 17.64% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 250.86K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.36.

Analyst Rating

Based on 4 analysts
Buy
Current Rating
9.000
Target Price
+101.79%
Upside Space

FAQs

How does TradingKey generate the Stock Score of TriSalus Life Sciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of TriSalus Life Sciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of TriSalus Life Sciences Inc’s performance and outlook.

How do we generate the financial health score of TriSalus Life Sciences Inc?

To generate the financial health score of TriSalus Life Sciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects TriSalus Life Sciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of TriSalus Life Sciences Inc.

How do we generate the company valuation score of TriSalus Life Sciences Inc?

To generate the company valuation score of TriSalus Life Sciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare TriSalus Life Sciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of TriSalus Life Sciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of TriSalus Life Sciences Inc.

How do we generate the earnings forecast score of TriSalus Life Sciences Inc?

To calculate the earnings forecast score of TriSalus Life Sciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on TriSalus Life Sciences Inc’s future.

How do we generate the price momentum score of TriSalus Life Sciences Inc?

When generating the price momentum score for TriSalus Life Sciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of TriSalus Life Sciences Inc’s prices. A higher score indicates a more stable short-term price trend for TriSalus Life Sciences Inc.

How do we generate the institutional confidence score of TriSalus Life Sciences Inc?

To generate the institutional confidence score of TriSalus Life Sciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about TriSalus Life Sciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of TriSalus Life Sciences Inc.

How do we generate the risk management score of TriSalus Life Sciences Inc?

To assess the risk management score of TriSalus Life Sciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of TriSalus Life Sciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of TriSalus Life Sciences Inc.